



SmartPA Criteria Proposal

Drug/Drug Class:	Corlanor® (ivabradine) Clinical Edit
First Implementation Date:	December 3, 2018
Revised Date:	May 7, 2020
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Corlanor® (ivabradine)

Why Issue Selected: Corlanor® (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker used in stable symptomatic heart failure. It is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. In 2019, Corlanor also received an indication for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older. Corlanor should not be used as a substitute for beta blockers unless the patient is on maximally tolerated doses of beta blockers or if beta blockers are contraindicated. Currently there is much more evidence for beta blockers in heart failure than for Corlanor. Beta blockers have been shown to decrease death due to heart failure, cardiovascular death, and all-cause mortality while Corlanor has only been shown to decrease death due to heart failure. Given the well-proven mortality benefits of beta-blocker therapy, it is important to initiate and up titrate these agents to target doses, as tolerated, before assessing the resting heart rate for consideration of initiation of Corlanor therapy.

Program-Specific Information:	Date Range FFS 07-01-2018 to 06-30-2019				
	Drug	Claims	Spend	Cost per unit	Cost per month
	Corlanor® 5mg tablet	398	\$156,327.91	\$7.12 NADAC	\$427.20 NADAC (5mg BID)
	Corlanor® 7.5mg tablet	95	\$40,967.60	\$7.05 NADAC	\$423.00 NADAC (7.5mg BID)
	Corlanor® 5mg/5ml soln	0	\$0	\$1.47 WAC	\$441.00 WAC (5mg BID)

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Corlanor® (ivabradine)
- Age range: All appropriate MO HealthNet participants aged **6 months** and older

Approval Criteria

- Documented history of Corlanor (ivabradine) therapy in the past 60 days **OR**
- **Prescribed by or in consultation with a cardiologist or other specialist for the treated disease state AND**
- **Participant aged ≥ 6 months and < 18 years:**
 - Documented diagnosis of heart failure due to dilated cardiomyopathy **AND**
 - Participant is in sinus rhythm **AND**
 - Participant has an appropriate heart rate for therapy based on age:
 - Aged 6-12 months: ≥ 105 beats per minute
 - Aged 1-3 years: ≥ 95 beats per minute
 - Aged 3-5 years: ≥ 75 beats per minute
 - Aged 5 years and older: ≥ 70 beats per minute **OR**
- Participant aged ≥ 18 years:
 - Documented therapy with a beta blocker for 60 out of the past 90 days **OR**
 - Documented contraindications to beta blocker therapy **AND**
 - Participant has a left ventricular ejection fraction of 35% or less **AND**
 - Participant is in sinus rhythm **AND**
 - Participant has a resting heart rate of at least 70 beats per minute **OR**
- Approval based on clinical consultant review

Denial Criteria

- Therapy will be denied if no approval criteria are met
- **Documented history of severe hepatic impairment in the past 2 years**

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

1 year

References

- CORLANOR® (ivabradine) [package insert]. Thousand Oaks, California: Amgen Inc.; April 2019.
- Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [published online May 20, 2016]. *Circulation*. [PubMed 27208050]10.1161/CIR.0000000000000435

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.